| Ms Jillian Rose Barry, CNP | |
|
291 Independence Dr, Chestnut Hill, MA 02467-3628 | |
| (617) 541-6500 | |
| Not Available |
| Full Name | Ms Jillian Rose Barry |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 291 Independence Dr, Chestnut Hill, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104529601 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | RN2308907 (Massachusetts) | Secondary |
| 363L00000X | Nurse Practitioner | RN2308907 (Massachusetts) | Primary |
| Entity Name | Atrius Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871639914 PECOS PAC ID: 4789588641 Enrollment ID: O20031121000582 |
News Archive
Flamel Technologies today announced its financial results for the first quarter of 2012.
New research from Trinity College Dublin suggests that older adults can be more focused, less impeded by anxiety and less mentally restless than younger adults.
Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.
Oregon Health & Science University is partnering with the University of Oregon and Harvard Medical School to expedite basic science research into new and existing drugs and compounds that may prevent the complications associated with Fanconi anemia, an inherited condition that can lead to bone marrow failure and cancer.
Poor sleep may impact treatment and recovery in veterans with Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI). A review of extensive research on sleep in TBI and PTSD has found that sleep-focused interventions can improve treatment outcomes in veterans.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Jillian Rose Barry, CNP 191 Clyde St, Chestnut Hill, MA 02467-2903 Ph: (508) 742-7181 | Ms Jillian Rose Barry, CNP 291 Independence Dr, Chestnut Hill, MA 02467-3628 Ph: (617) 541-6500 |
News Archive
Flamel Technologies today announced its financial results for the first quarter of 2012.
New research from Trinity College Dublin suggests that older adults can be more focused, less impeded by anxiety and less mentally restless than younger adults.
Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.
Oregon Health & Science University is partnering with the University of Oregon and Harvard Medical School to expedite basic science research into new and existing drugs and compounds that may prevent the complications associated with Fanconi anemia, an inherited condition that can lead to bone marrow failure and cancer.
Poor sleep may impact treatment and recovery in veterans with Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI). A review of extensive research on sleep in TBI and PTSD has found that sleep-focused interventions can improve treatment outcomes in veterans.
› Verified 4 days ago